Prostate-specific Antigen Testing and Prostate Cancer Screening

Primary Care - Clinics in Office Practice

Volumn 37, Issue 3, 2010, Pages 441-459

  Djavan, Bob ^a   Eckersberger, Elisabeth ^a   Finkelstein, Julia ^a   Sadri, Helen ^a   Taneja, Samir S ^a   Lepor, Herbert ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Free PSA; Prostate Cancer; PSA; Screening

Indexed keywords

CYTOCHROME P450 3A4; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE;

AGE; ATTITUDE TO ILLNESS; CANCER EPIDEMIOLOGY; CANCER IMMUNOLOGY; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CANCER STATISTICS; CANCER SURVIVAL; CLINICAL TRIAL; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; FALSE POSITIVE RESULT; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATITIS; QUALITY OF LIFE; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

EID: 77955495389     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2010.05.001     Document Type: Review

References (90)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., et al. Cancer statistics 2001. CA Cancer J Clin 2001, 51:15-37.
2. Eyre H., Kahn R., Robertson R.M., et al. Preventing cancer, cardiovascular disease, and diabetes. A common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Circulation 2004, 109:3244-3255.
3. Hsing A.W., Tsao L., Devesa S.S. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000, 85:60-67.
4. Stephenson R.A. Prostate cancer trends in the era of prostate specific antigen: an update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am 2002, 29:173-178.
5. Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2006 National Cancer Institute. Bethesda (MD). Available at:, Accessed June 10, 2010. Based on November 2008 SEER data submission, posted to the SEER Web site, 2009. http://seer.cancer.gov/csr/1975_2006/.
6. Ross R.K., Bernstein L., Lobo R.A., et al. 5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992, 339:887-889.
7. Ross R.K., Coetzee G.A., Reichardt J., et al. Does the racial-ethnic variation in prostate cancer risk have a hormonal basis?. Cancer 1995, 75:1778-1792.
8. Makridakis N.M., Ross R.K., Pike M.C., et al. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African American and Hispanic men in Los Angeles. Lancet 1999, 354:975-978.
9. Hardy D.O., Scher H.I., Bogenreider T., et al. Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin Endocrinol Metab 1996, 81:4400-4405.
10. Ross R.K., Henderson B.E. Do diet and androgen alter prostate cancer risk via a common etiologic pathway?. J Natl Cancer Inst 1994, 86:252-254.
11. Paris P.L., Kupelian P.A., Hall J.M., et al. Association between CYP3A4 genetic variant and clinical presentation in African American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 1998, 8:901-905.
12. Kolonel L.N., Nomura A.M., Cooney R.V. Dietary fat and prostate cancer: current status. J Natl Cancer Inst 1999, 91:414-428.
13. Denis L., Morton M.S., Griffiths K. Diet and its preventive role in prostatic disease. Eur Urol 1999, 35:377-387.
14. Hsing A.W., Devesa S.S., Jin F., et al. Rising incidence of prostate cancer in Shanghai. Cancer Epidemiol Biomarkers Prev 1998, 7:83-84.
15. Paeratakul S., Popkin B.M., Keyou G., et al. Changes in diet and physical activity affect the body mass index of Chinese adults. Int J Obes Relat Metab Disord 1998, 22:424-431.
16. Djavan B., Eckersberger E., Espinosa G., et al. Complex mechanisms in prostatic inflammatory response. Eur Urol 2009, 8(13):872-878.
17. Margreiter M., Stangelberger A., Valimberti E., et al. Biomarkers for early prostate cancer detection. Minerva Urol Nefrol 2008, 60:51-60.
18. Riegman P.H., Vlietstra R.J., Klaassen P., et al. The prostate-specific antigen gene and the human glandular kallikrein-1 gene are tandemly located on chromosome 19. FEBS Lett 1989, 247(1):123-126.
19. Boccon-Gibod L. Rising PSA with negative biopsy. Eur Urol 2001, 40(Suppl 2):3-8.
20. Brawer M.K., Cheli C.D., Neaman I.E., et al. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 2000, 163:1476-1480.
21. Schwartz K.L., Grignon D.J., Sakr W.A., et al. Prostate cancer histologic trends in the Metropolitan Detroit area, 1982 to 1996. Urology 1999, 53:769-774.
22. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of percentage of free prostate specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998, 279:1542-1547.
23. Roehl K.A., Han M., Ramos C.G., et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004, 172:910-914.
24. Partin A.W., Mangold L.A., Lamm D.M., et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001, 58:843-848.
25. Kattan M.W., Eastham J.A., Stapleton A.M., et al. A preoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998, 90:766-771.
26. Kattan M.W., Zelefsky M.J., Kupelian P.A., et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000, 18:3352-3359.
27. Kattan M.W., Potters L., Blasko J.C., et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 2001, 58:393-399.
28. Catalona W.J., Smith D.S., Ratliff T.L., et al. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991, 324:1156-1161.
29. Bretton P.R. Prostate specific antigen and digital rectal examination in screening for prostate cancer: a community based study. South Med J 1994, 87:720-723.
30. Catalona W.J., Smith D.S., Ratliff T.L., et al. Detection of organ confined prostate cancer is increased through prostate specific antigen based screening. JAMA 1993, 270:948-954.
31. Catalona W.J., Smith D.S., Ornstein D.K. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997, 277:1452-1455.
32. Catalona W.J., Partin A.W., Finlay J.A., et al. Use of percentage of free prostate specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/ml and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 1999, 54:220-224.
33. Djavan B., Zlotta A., Kratzik C., et al. PSA, PSA density, PSA density of transitional zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/ml. Urology 1999, 54:517-522.
34. Babaian R.J., Fritsche H., Ayala A., et al. Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/ml. Urology 2000, 56:1000-1006.
35. Bostwick D.G., Gould V.E., Qian J., et al. Prostate cancer detected by uPM3: radical prostatectomy findings. Mod Pathol 2006, 19(5):630-633.
36. Sun L., Gancarczyk K., Paquette E.L., et al. Introduction to the Department of Defense Center for Prostate Disease Research Multicenter National Prostate Cancer Database and analysis in the PSA era. Urol Oncol 2001, 203-209.
37. Stephenson R.A., Stanford J.L. Population-based prostate cancer trends in the United States: patterns of change in the era of prostate specific antigen. World J Urol 1997, 15:331-335.
38. Djavan B., Zlotta A.R., Byttebier G., et al. Prostate specific antigen density of the transitional zone for early detection of prostate cancer. J Urol 1998, 160:411-419.
39. Djavan B., Zlotta A., Remzi M., et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1051 patients. J Urol 2000, 163:1144-1149.
40. Stamey T.A., Yang N., Hay A.R., et al. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987, 317:909-916.
41. Babaian R.J., Fritsche H.A., Evans R.B. Prostate specific antigen and prostate gland volume: correlation and clinical application. J Clin Lab Anal 1990, 4:135-137.
42. Benson M.C., Whang I.S., Olsson C.A., et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992, 147:817-821.
43. Morote J., Raventos C.X., Lorente J.A., et al. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng/ml. J Urol 1997, 158:502-504.
44. Kuriyama M., Uno H., Watanabe H., et al. Determination of reference values for total PSA, F/T and PSAD according to prostatic volume in Japanese prostate cancer patients with slightly elevated serum PSA levels. Jpn J Clin Oncol 1999, 29:617-622.
45. Reissigl A., Horninger W., Fink K., et al. Prostate cancer screening in the county of Tyrol, Austria: experience and results. Cancer 1997, 80:1818-1829.
46. Borer J.G., Sherman J., Solomon M.C., et al. Age specific prostate specific antigen reference ranges: population specific. J Urol 1998, 159:444-448.
47. Schmid H.P., McNeal J.E., Stamey T.A. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993, 71(6):2031-2040.
48. Carter H.B., Morrell C.H., Pearson J.D., et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 1992, 52(12):3323-3328.
49. Ornstein D.K., Smith D.S., Rao G.S., et al. Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. J Urol 1997, 157(6):2179-2182.
50. Nixon R.G., Wener M.H., Smith K.M., et al. Day to day changes in free and total PSA: significance of biological variation. Prostate Cancer Prostatic Dis 1997, 1(2):90-96.
51. Porter J.R., Hayward R., Brawer M.K. The significance of short term PSA change in men undergoing ultrasound guided prostate biopsy. J Urol 1994, 264(Suppl):239A.
52. Nixon R.G., Meyer G.E., Blase A.B., et al. Comparison of three investigational assays for the free form of prostate specific antigen. J Urol 1998, 160:420-425.
53. Brawer M.K., Meyer G.E., Letran J.L., et al. Measurement of complexed PSA improves the specificity for early detection of prostate cancer. Urology 1998, 52:372-378.
54. Okegawa T., Noda H., Nutahara K., et al. Comparison of two investigational assays for the complexed prostate specific antigen in total prostate specific antigen between 4.0 and 10.0 ng/ml. Urology 2000, 55:700-704.
55. Mitchell I.D., Croal B.L., Dickie A., et al. A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. J Urol 2001, 165:49-53.
56. Miller M.C., O'Dowd G.J., Partin A.W., et al. Contemporary use of complexed PSA and calculated per cent free PSA for early detection of prostate cancer: impact of changing demographics. Urology 2001, 57:1105-1111.
57. Djavan B., Remzi M., Zlotta A.R., et al. Complexed prostate specific antigen, complexed prostate specific antigen density of total and transitional zone, complexed/total prostate specific antigen ratio, free-to-total prostate specific antigen ratio, density of total and transition zone prostate specific antigen: results of the prospective multicenter European trial. Urology 2002, 60:4-9.
58. Okihara K., Cheli C.D., Partin A.W., et al. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen, and their ratio in detecting prostate cancer. J Urol 2002, 167:2017-2023.
59. Stamey T.A., Yemoto C.E. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transitional zone volume. J Urol 2000, 163:119-124.
60. Partin A.W., Brawer M.K., Bartsch G., et al. Complexed prostate specific antigen improves the specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol 2003, 170:1787-1791.
61. Horninger W., Cheli C.D., Babaian R.J., et al. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. Urology 2002, 60(4 Suppl 1):31-35.
62. Nurmikko P., Vaisanen V., Piironen T., et al. Production and characterization of novel anti-prostate specific antigen (PSA) monoclonal antibodies that do not detect the internally cleaved Lys145-Lys146 inactive PSA. Clin Chem 2000, 46:1610-1618.
63. Nurmikko P., Pettersson K., Piironen T., et al. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate specific antigen lacking an internal cleavage site at Lys145-Lys146. Clin Chem 2001, 47:1415-1423.
64. Steuber T., Nurmikko P., Haese A., et al. Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. J Urol 2002, 168:1917-1922.
65. Linton H.J., Marks L.S., Millar L.S., et al. Benign prostate specific antigen (BPSA) in serum is increased in benign prostate disease. Clin Chem 2003, 49:253-259.
66. Mikolajczyk S.D., Millar L.S., Marker K.M., et al. Seminal plasma contains " BPSA" , a molecular form of prostate specific antigen that is associated with benign prostatic hyperplasia. Prostate 2000, 45:271-276.
67. Mikolajczyk S.D., Millar L.S., Wang T.J., et al. A precursor form of prostate specific antigen is highly elevated in prostate cancer compared with benign transitional zone prostate tissue. Cancer Res 2000, 60:756-759.
68. Mikolajczyk S.D., Grauer L.S., Millar L.S., et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 1997, 50:710-714.
69. Mikolajczyk S.D., Marker K.M., Millar L.S., et al. A truncated precursor form of prostate specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001, 61:6958-6963.
70. Peter J., Unverzagt C., Krogh T.N., et al. Identification of precursor forms of free prostate specific antigen in serum of prostate cancer patients by immunosorption and spectrometry. Cancer Res 2001, 61:957-962.
71. Mikolaiczyk S.D., Rittenhouse H.G. Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer. Keio J Med 2003, 52:86-89.
72. Sokoll L.J., Chan D.W., Mikolajczyk S.D. Proenzyme PSA for the early detection of prostate cancer in the 2.5-4.0 ng/ml total PSA range: preliminary analysis. Urology 2002, 59:261-265.
73. Catalona W.J., Bartsch G., Rittenhouse H.G., et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2.4-4 ng/ml. J Urol 2003, 170:2181-2185.
74. Carter H.B., Epstein J.I., Partin A.W. Influence of age and prostate specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. Urology 1999, 53:126-130.
75. Smith C.V., Bauer J.J., Connelly R.R., et al. Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database. J Urol 2000, 164:1964-1967.
76. Humphrey P.A., Keetch D.W., Smith D.S., et al. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol 1996, 155:816-820.
77. Anast J.W., Andriole G.L., Bismar T.A., et al. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screened population?. Urology 2004, 64:544-550.
78. Gilliland F.D., Hunt W.C., Key C.R. Improving survival for patients with prostate cancer diagnosed in the prostate specific antigen era. Urology 1996, 48:67-71.
79. Paquette E.L., Connelly R.R., Sesterhenn I.A., et al. Improvements in pathologic staging for African American men undergoing radical retropubic prostatectomy during the prostate specific antigen era: implications for screening a high-risk group for prostate carcinoma. Cancer 2001, 92:2673-2679.
80. Albertson P.C., Fryback D.G., Storer B.E., et al. Long term survival among men with conservatively treated localized prostate cancer. JAMA 1995, 274:626-631.
81. Canfield S. Commentary; annual screening for prostate cancer did not reduce mortality from prostate cancer. Evidence Based Med 2009, 150:4-5.
82. Bartsch G., Horninger W., Klocker H., et al. Prostate cancer mortality after introduction of prostate specific antigen mass screening in the federal state of Tyrol, Austria. Urology 2001, 58:417-424.
83. Schröder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-1328.
84. Andriole G.L., Crawford E.D., Grubb R.L., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360:1310-1319.
85. Croswell J.M., Kramer B.S., Kreimer A.R., et al. Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med 2009, 7:212-222.
86. Draisma G., Boer R., Otto S.J., et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003, 95:868-878.
87. McNaughton-Collins M., Fowler F.J., Caubet J.F., et al. Psychological effects of a suspicious prostate cancer screening test followed by a benign biopsy result. Am J Med 2004, 117:719-725.
88. Kobuke M., Saika T., Nakanishi Y. Prospective longitudinal comparative study of health-related quality of life in patients with radical prostatectomy or permanent brachytherapy for prostate cancer. Acta Med Okayama 2009, 63:129-135.
89. Cordon-Cardo C., Kotsianti A., Verbel D.A., et al. Improved prediction of prostate cancer recurrence through systems pathology. J Clin Invest 2007, 117:1876-1883.
90. Smith R.A., Von Eschenbach A.C., Wender R., et al. American cancer society guidelines for early detection of cancer: Update of early detection guidelines for prostate, colorectal and endometrial cancers. CA Cancer J Clin 2001, 51:38-75.